What Is Neuropeptide FF? Definition and What Research Reports

Definition

Neuropeptide FF (NPFF) is a small, naturally occurring neuropeptide belonging to the RFamide peptide family — a group named for the arginine-phenylalanine-amide sequence at the C-terminal end of each peptide. It is produced in the body from a larger precursor protein and is released by neurons and, as later work has described, by some non-neuronal tissues. NPFF exerts its effects by binding two closely related G protein-coupled receptors, NPFFR1 and NPFFR2, which are the subject of ongoing structural and medicinal-chemistry research (PMID 32673481). In the peptide literature, "Neuropeptide FF" refers to this endogenous ligand and, by extension, to the receptor system it activates.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question. Nothing here describes how any substance should be used, and no dosing information is provided because the referenced publications are cited here for their reported findings only.

What Class of Molecule It Is and Where It Comes From

NPFF sits in the RFamide neuropeptide class, alongside related peptides such as prolactin-releasing peptide. Structurally it is a short peptide chain, and it is processed from a precursor that also gives rise to related RFamide sequences. RFamide peptides are evolutionarily old: NPFF-related genes have been identified and characterised outside mammals, including in the fish species Larimichthys polyactis, where researchers described the gene's sequence, tissue distribution and a potential anti-inflammatory function (PMID 35503491).

The receptors are equally central to the definition. A 2025 structural study in Cell Reports reported cryo-EM-based structures that clarified how peptide ligands are recognised by neuropeptide FF receptors and how that recognition can be modulated (PMID 40839429). A 2020 review in the Journal of Medicinal Chemistry summarised NPFF receptor pharmacology and the development of ligands aimed at these targets (PMID 32673481).

How the Term Is Used in Peptide Research

In research writing, "Neuropeptide FF" is used in three overlapping ways:

• The endogenous ligand — the peptide itself, measured or administered in laboratory models to probe what the system does.
• The receptor system — shorthand for NPFFR1/NPFFR2 signalling, as in phrases like "NPFF receptor agonism."
• A design element in hybrid molecules — NPFF receptor pharmacology has been built into conjugate compounds studied alongside opioid receptor activity (PMID 40854312).

NPFF is an investigational and physiological subject, not an approved therapeutic product. Peptides of this kind appear in the literature as laboratory reagents and research targets, and publications describing them do not establish clinical use.

What the Published Literature Reports

Pain, opioid systems and sensory signalling

The NPFF system has long been studied for its interaction with opioid signalling. A 2025 study in the British Journal of Pharmacology described a novel peptide–fentanyl conjugate with combined μ-opioid and neuropeptide FF receptor agonism, and the researchers reported that it produced antinociception with limited side effects in male mice (PMID 40854312). In a separate line of work on sensory neurons, a 2020 report in The Journal of Headache and Pain found that NPFF receptor 2 inhibited capsaicin-induced upregulation of CGRP in mouse trigeminal ganglion (PMID 32640973).

Cortical excitability

A 2015 study in Epilepsia reported that NPFF and prolactin-releasing peptide decreased cortical excitability through activation of NPFF receptors (PMID 25684325). That work placed the NPFF system among neuromodulators examined in the context of excitability control.

Immune and metabolic biology

NPFF research expanded beyond the nervous system when a 2017 paper in The Journal of Clinical Investigation reported that NPFF increased M2 activation and self-renewal of adipose tissue macrophages (PMID 28581443). More recently, a 2024 study in Immunity described a GPCR–neuropeptide axis that dampened hyperactive neutrophils by promoting an alternative-like polarisation during bacterial infection (PMID 38295799). In a non-mammalian model, researchers reported a potential anti-inflammatory function for an NPFF-related gene in fish (PMID 35503491).

Kidney and blood pressure

A 2024 paper in Scientific Reports examined renal autocrine NPFF signalling and reported that it regulates blood pressure, extending the peptide's described biology into the kidney (PMID 38965251).

Neuronal survival after ischaemic injury

A 2024 study in the International Journal of Molecular Sciences reported that NPFF promoted neuronal survival and enhanced synaptic protein expression following ischaemic injury in a laboratory model (PMID 39519132).

Reproductive biology in fish models

Two studies in medaka examined reproductive roles. One reported that NPFF indirectly affected testicular morphogenesis and function (PMID 36343231), and a 2022 Endocrinology paper reported that co-existing NPFF and gonadotropin-releasing hormone 3 coordinately modulated male sexual behaviour (PMID 34962983).

Snapshot of Cited Findings

Tolerability: What Studies Report

The verified literature summarised here does not include human safety trials of NPFF. The closest tolerability observation comes from the 2025 mouse study, in which researchers reported that a conjugate with μ-opioid and NPFF receptor agonism produced antinociception with limited side effects in male mice (PMID 40854312). A 2020 review discussed NPFF receptor ligand development and therapeutic applications, which is a research-stage discussion rather than a description of established clinical safety (PMID 32673481). No adverse-event profile for NPFF in humans can be drawn from these sources.

Limitations of the Current Evidence

• Model species. Several key findings come from mice, fish and cell systems, including work in medaka (PMID 34962983) and in Larimichthys polyactis (PMID 35503491); results in these systems do not transfer automatically to people.
• Receptor complexity. NPFFR1 and NPFFR2 have overlapping pharmacology, and structural work has focused on how ligands are recognised and modulated at these receptors (PMID 40839429).
• Breadth without depth. Reported roles span pain, immunity, blood pressure and reproduction, but each area rests on a small number of studies.

For readers building a working vocabulary of peptide biology, NPFF is best understood as an endogenous RFamide signalling molecule and a receptor system under active laboratory investigation — a research subject, not a consumer product. Again, this entry is educational only and is not medical advice.

References

• Neuropeptide FF and Its Receptors: Therapeutic Applications and Ligand Development (Journal of Medicinal Chemistry, 2020)
• Structural basis of peptide recognition and modulation for neuropeptide FF receptors (Cell Reports, 2025)
• A novel peptide-fentanyl conjugate with μ-opioid and neuropeptide FF receptor agonism produces antinociception with limited side effects in male mice (British Journal of Pharmacology, 2025)
• Neuropeptide FF receptor 2 inhibits capsaicin-induced CGRP upregulation in mouse trigeminal ganglion (The Journal of Headache and Pain, 2020)
• Neuropeptide FF and prolactin-releasing peptide decrease cortical excitability through activation of NPFF receptors (Epilepsia, 2015)
• Neuropeptide FF increases M2 activation and self-renewal of adipose tissue macrophages (The Journal of Clinical Investigation, 2017)
• A GPCR-neuropeptide axis dampens hyperactive neutrophils by promoting an alternative-like polarization during bacterial infection (Immunity, 2024)
• Renal autocrine neuropeptide FF (NPFF) signaling regulates blood pressure (Scientific Reports, 2024)
• Neuropeptide FF Promotes Neuronal Survival and Enhances Synaptic Protein Expression Following Ischemic Injury (International Journal of Molecular Sciences, 2024)
• Neuropeptide FF indirectly affects testicular morphogenesis and functions in medaka (PNAS, 2022)
• Co-existing Neuropeptide FF and Gonadotropin-Releasing Hormone 3 Coordinately Modulate Male Sexual Behavior (Endocrinology, 2022)
• Neuropeptide FF-related gene in fish (Larimichthys polyactis): identification, characterization, and potential anti-inflammatory function (Molecular Biology Reports, 2022)